- Home
- KBR vs LEGN Comparison
KBR vs LEGN Comparison
Compare KBR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- LEGN
- Stock Information
- Founded
- KBR 1901
- LEGN 2014
- Country
- KBR United States
- LEGN United States
- Employees
- KBR N/A
- LEGN N/A
- Industry
- KBR Military/Government/Technical
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- LEGN Health Care
- Exchange
- KBR Nasdaq
- LEGN Nasdaq
- Market Cap
- KBR 6.3B
- LEGN 5.4B
- IPO Year
- KBR 2006
- LEGN 2020
- Fundamental
- Price
- KBR $47.62
- LEGN $35.64
- Analyst Decision
- KBR Buy
- LEGN Strong Buy
- Analyst Count
- KBR 7
- LEGN 13
- Target Price
- KBR $64.33
- LEGN $75.17
- AVG Volume (30 Days)
- KBR 1.5M
- LEGN 2.0M
- Earning Date
- KBR 07-31-2025
- LEGN 08-08-2025
- Dividend Yield
- KBR 1.39%
- LEGN N/A
- EPS Growth
- KBR N/A
- LEGN N/A
- EPS
- KBR 2.98
- LEGN N/A
- Revenue
- KBR $7,979,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- KBR $14.27
- LEGN $65.49
- Revenue Next Year
- KBR $8.57
- LEGN $53.76
- P/E Ratio
- KBR $15.99
- LEGN N/A
- Revenue Growth
- KBR 12.84
- LEGN 112.46
- 52 Week Low
- KBR $43.89
- LEGN $27.34
- 52 Week High
- KBR $72.60
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- KBR 33.92
- LEGN 57.79
- Support Level
- KBR $46.54
- LEGN $32.42
- Resistance Level
- KBR $48.62
- LEGN $36.91
- Average True Range (ATR)
- KBR 1.26
- LEGN 1.42
- MACD
- KBR -0.30
- LEGN 0.02
- Stochastic Oscillator
- KBR 13.78
- LEGN 67.58
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.